Safety and Feasibility of Paired Vagus Nerve Stimulation With Rehabilitation for Improving Upper Extremity Function in People With Cervical Spinal Cord Injury
Safety and Feasibility of Paired Vagus Nerve Stimulation With Rehabilitation for Improving Upper Extremity Function in People With Cervical Spinal Cord Injury: A Pilot Randomized Control Trial.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Radha Korupolu, MD
- Phone Number: 713-797-5233
- Email: Radha.Korupolu@uth.tmc.edu
Study Contact Backup
- Name: Alyssa Miller
- Phone Number: 713-797-7132
- Email: Alyssa.Miller@uth.tmc.edu
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas Health Science Center at Houston
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- a diagnosis of traumatic incomplete (AIS B-D) cervical spinal cord injury (C8 and above)
- at least 12 months post-traumatic SCI
- demonstrate some residual movement in the upper limb (e.g., able to perform pinch movement with thumb and index finger)
- meet all clinical criteria for the surgical VNS implantation as determined by the PI, neurosurgeon, and anesthesiologist.
Exclusion Criteria:
- non-traumatic SCI, injury
- presence of ongoing dysphasia or aspiration difficulties
- evidence of vagus pre-existing vocal cord paralysis as determined with laryngoscopy procedure
- participants with prior left-sided anterior cervical surgery who exhibit too much of scar tissue at the surgery site which will be determined by neurosurgeon
- concomitant clinically significant brain injury
- history of prior injury to a vagus nerve
- receiving medication that may significantly interfere with the actions of VNS on neurotransmitter systems at study entry
- other comorbidities or complications that will hinder or contraindicate surgical procedure
- medical or mental instability
- pregnancy or plans to become pregnant during the study period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Treatment group
Participants in the treatment group will receive 18 goal-directed upper extremity rehabilitation therapy sessions with paired VNS over six weeks.
Followed by 90 days home exercise program.
|
An implantable system consisting of an implantable neurostimulator (model 1001 Implantable Pulse Generator (IPG)) and an implantable lead and electrode (Model 30000 VNS lead) will be used.
An external system consisting of an external controller (Model 2000 Wireless Transmitter) and an external software system (computer and Model 4001 Microtransponder SAPS® software) will provide clinical control of settings for the implantable pulse generator (IPG) .
All VNS devices (Vivistim System® ) will be provided as a donation by Microtransponder Inc.
The device is programmed to stimulate for 0.5s on each button push.
After surgical recovery, participants will receive five stimulations in reducing strength (starting at 0.8mA and then reducing to 0.1mA each step) at the beginning of each therapy session, followed by stimulation (0.8 mA)
. The rehabilitation therapy involves arm and hand exercises with objects.
The therapist will select these exercises based on movement abilities.
Tasks will be selected from six functional task categories: reach and grasp, gross movement, object flipping, simulated eating tasks, inserting objects, and opening containers.
Approximately 30-50 repetitions will be performed in each category.
On average, 300-500 repetitions will be performed during each session within 1.5-2hours.
|
|
Sham Comparator: Control Group
Participants in the control group will receive 18 goal-directed upper extremity rehabilitation therapy sessions with sham VNS over six weeks.
Followed by 90 days home exercise program.
|
. The rehabilitation therapy involves arm and hand exercises with objects.
The therapist will select these exercises based on movement abilities.
Tasks will be selected from six functional task categories: reach and grasp, gross movement, object flipping, simulated eating tasks, inserting objects, and opening containers.
Approximately 30-50 repetitions will be performed in each category.
On average, 300-500 repetitions will be performed during each session within 1.5-2hours.
An implantable system consisting of an implantable neurostimulator (model 1001 Implantable Pulse Generator (IPG)) and an implantable lead and electrode (Model 30000 VNS lead) will be used.
An external system consisting of an external controller (Model 2000 Wireless Transmitter) and an external software system (computer and Model 4001 Microtransponder SAPS® software) will provide clinical control of settings for the implantable pulse generator (IPG) .
All VNS devices (Vivistim System® ) will be provided as a donation by Microtransponder Inc.
The device is programmed to stimulate for 0.5s on each button push.
After surgical recovery, participants will receive five stimulations in reducing strength (starting at 0.8mA and then reducing to 0.1mA each step) at the beginning of each therapy session, followed by stimulation (0 mA)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety as assessed by number of subjects with post surgical complications
Time Frame: 90-day follow-up
|
post-surgical complications include but are not limited to dysphagia, hematoma, hoarseness of voice, vocal cord paralysis, edema, pain, and post-surgical infection
|
90-day follow-up
|
|
Safety as assessed by number of subjects with change in systolic blood pressure
Time Frame: pretreatment, post treatment (about 6 weeks after pre treatment )
|
pretreatment, post treatment (about 6 weeks after pre treatment )
|
|
|
Safety as assessed by number of subjects with change in diastolic blood pressure
Time Frame: pretreatment, post treatment (about 6 weeks after pre treatment )
|
pretreatment, post treatment (about 6 weeks after pre treatment )
|
|
|
Safety as assessed by number of subjects with change in heart rate
Time Frame: pretreatment, post treatment (about 6 weeks after pre treatment )
|
pretreatment, post treatment (about 6 weeks after pre treatment )
|
|
|
Safety as assessed by number of subjects with change in respiratory rate
Time Frame: pretreatment, post treatment (about 6 weeks after pre treatment )
|
pretreatment, post treatment (about 6 weeks after pre treatment )
|
|
|
Safety as assessed by number of subjects with change in autonomic dysreflexia
Time Frame: pretreatment, post treatment (about 6 weeks after pre treatment )
|
pretreatment, post treatment (about 6 weeks after pre treatment )
|
|
|
Safety as assessed by number of subjects with worsening spasticity
Time Frame: pretreatment, post treatment (about 6 weeks after pre treatment )
|
pretreatment, post treatment (about 6 weeks after pre treatment )
|
|
|
Safety as assessed by number of subjects with change in pain at stimulation site
Time Frame: pretreatment, post treatment (about 6 weeks after pre treatment )
|
pretreatment, post treatment (about 6 weeks after pre treatment )
|
|
|
Feasibility as assessed by the number of participants that completed all the sessions
Time Frame: end of study(about 132 days after enrollment)
|
end of study(about 132 days after enrollment)
|
|
|
Feasibility as assessed by the number of participants that dropped out of the study
Time Frame: end of study(about 132 days after enrollment)
|
end of study(about 132 days after enrollment)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in hand function as assessed by the Toronto Rehab Institute Hand Function Test (TRI-HFT)
Time Frame: baseline, post-treatment (first day after 6 week inclinic therapy), 30 days, and 90 days follow-up.
|
This is a 14 item questionnaire and each is scored from 1(no movement elicited) to 8(normal grasp) a higher number indicating better hand function
|
baseline, post-treatment (first day after 6 week inclinic therapy), 30 days, and 90 days follow-up.
|
|
Change in capability of using arms and hands as assessed by the Capabilities of Upper Extremity Questionnaire (CUE-Q)
Time Frame: baseline, post-treatment (first day after 6 week inclinic therapy), 30 days, and 90 days follow-up.
|
This is a 17 item questionnaire and each is scored from 1(totally limited) to 7(not at all limited), a higher number indicating better outcome
|
baseline, post-treatment (first day after 6 week inclinic therapy), 30 days, and 90 days follow-up.
|
|
Change in self care independence as assessed by the Spinal Cord Injury Independence Measure-III (SCIM-III) self-care subscore
Time Frame: baseline, post-treatment (first day after 6 week inclinic therapy), 30 days, and 90 days follow-up.
|
This is a 4 item questionnaire and each is scored from 0(need total assistance) to 3(completely independent), higher score indicating more independence.
|
baseline, post-treatment (first day after 6 week inclinic therapy), 30 days, and 90 days follow-up.
|
|
Quality of Life as assessed by the Spinal Cord Injury- Quality of Life (SCI-QoL) questionnaire
Time Frame: baseline, post-treatment (first day after 6 week inclinic therapy), 30 days, and 90 days follow-up.
|
This questionnaire has 3 parts:
|
baseline, post-treatment (first day after 6 week inclinic therapy), 30 days, and 90 days follow-up.
|
|
Change in Pain as assessed by the International SCI pain basic data subset (version 2).
Time Frame: baseline, post-treatment (first day after 6 week inclinic therapy), 30 days, and 90 days follow-up.
|
This is an 6 item questionnaire and each is scored from 0 (no pain) -10 (pain as bad as you can imagine), a higher score indicating more pain.
|
baseline, post-treatment (first day after 6 week inclinic therapy), 30 days, and 90 days follow-up.
|
|
Change in Depression as assessed by the Patient Health Questionnaire (PHQ-8)
Time Frame: baseline, post-treatment (first day after 6 week inclinic therapy), 30 days, and 90 days follow-up.
|
This is an eight item questionnaire and each is scored from 0(not at all) to 3(nearly every day) a higher score indicating worse outcome
|
baseline, post-treatment (first day after 6 week inclinic therapy), 30 days, and 90 days follow-up.
|
|
Change in degree of upper limb impairment as assessed by the Graded Redefined Assessment of Strength Sensibility and Prehension (GRASSP) survey.
Time Frame: baseline, post-treatment (first day after 6 week inclinic therapy), 30 days, and 90 days follow-up.
|
The 3 measured domains are as follows:
|
baseline, post-treatment (first day after 6 week inclinic therapy), 30 days, and 90 days follow-up.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Radha Korupolu, The University of Texas Health Science Center, Houston
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HSC-MS-22-0579
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.